The IgAN group needs to be congratulated for coordinating a worldwide effort to develop a universally accepted IgAN classification system. By developing agreed definitions for each pathological ...

The acquisition would significantly boost Novartis’ position in rare kidney disease IgA nephropathy (IgAN), which the Swiss big pharma is targeting with oral complement factor B inhibitor ...

Novartis has claimed accelerated approval from the FDA for a second indication for Fabhalta – IgA nephropathy (IgAN) – as it charts a course to blockbuster sales for the drug. The US regulator ...